CLAIMS

1. A method of producing a biological product using an insect cell, wherein the insect cell is an Sf9 or Sf21 cell, or a cell passaged therefrom, wherein the insect cell is free of a viral genome having at least 70% homology to SEQ ID NO: 1, and wherein the method comprises the steps of:

a) providing the insect cell; and

b) producing the biological product in said cell.

2. The method of claim 1, wherein the insect cell is an Sf9 cell.

3. The method of claim 2, wherein the Sf9 cell is derived from the cell line deposited as ATCC CRL-1711.

4. The method of claim 1, wherein the insect cell is an Sf21 cell.

5. The method of claim 1, wherein the biological product is for therapeutic or diagnostic purposes.

6. The method of claim 1, wherein the biological product is a protein, peptide, drug substance, virus-like particle (VLP), antibody, growth factor, polysaccharide, nucleic acid, virus, or vaccine antigen.

7. The method of claim 1, wherein the biological product is DNA.

8. The method of claim 1, wherein the biological product is RNA.

9. The method of claim 1, wherein the biological product is a recombinant virus for gene therapy.

10. The method of claim 1, wherein the biological product is a therapeutic protein or an enzyme.

11. The method of claim 1, wherein the biological product is a Calicivirus VLP.

12. The method of claim 1, wherein the biological product is a Norovirus VLP.

13. The method of claim 1, wherein the biological product is a protein and the protein is glycosylated.

14. The method of claim 1, wherein the insect cell is free of a viral genome having at least 70% homology to SEQ ID NO:1.

15. The method of claim 1, wherein the insect cell is free of a viral genome comprising the sequence according to SEQ ID NO:1.

16. The method of claim 1, wherein the biological product is a protein.

17. The method of claim 1, wherein the biological product is a peptide.

18. The method of claim 1, wherein the biological product is a drug substance.

19. The method of claim 1, wherein the biological product is a virus-like particle (VLP).

20. The method of claim 1, wherein the biological product is an antibody.

21. The method of claim 1, wherein the biological product is a growth factor.

22. The method of claim 1, wherein the biological product is a polysaccharide.

23. The method of claim 1, wherein the biological product is a nucleic acid.

24. The method of claim 1, wherein the biological product is a virus.

25. The method of claim 1, wherein the biological product is a vaccine antigen.

26. The method of claim 1, wherein the cell is comprised in a baculovirus-insect cell expression system.

27. The method of claim 1, wherein the insect cell is passaged from an Sf9 cell.

28. The method of claim 27, wherein the Sf9 cell is derived from the cell line deposited as ATCC CRL-1711.

29. A method of producing a biological product in an insect cell, the method comprising the steps of:

a) providing the insect cell,

b) confirming the absence of a viral genome having at least 95% homology to SEQ ID NO: 1 in the insect cell, and

c) producing the biological product in the insect cell,

wherein the insect cell is an Sf9 or Sf21 cell, or a cell passaged therefrom.

30. A biological product derived from an Sf9 or Sf21 cell, or a cell passaged therefrom, wherein the biological product comprises a nucleic acid, and wherein the biological product is free of a viral genome having at least 70% homology to SEQ ID NO: 1.

31. The biological product of claim 30, wherein the viral genome comprises a sequence having at least 85% homology to SEQ ID NO: 1.

32. The biological product of claim 30, wherein the viral genome comprises a sequence according to SEQ ID NO: 1.

33. The biological product of claim 30 or 31, wherein the cell is an Sf9 cell.

34. The biological product of claim 32, wherein the Sf9 cell is derived from the cell line deposited as ATCC CRL-1711.

35. The biological product of claim 30, wherein the biological product is a DNA, RNA, vaccine, virus, or a virus-like particle preparation.

36. The biological product of claim 35, wherein the virus is a recombinant virus for gene therapy.